AGN 192836 is a potent and selective α2 adrenergic agonist with EC 50 s of 8.7, 41 and 6.6 nM for α2A, α2B and α2C receptor, respectively. In Vitro Binding assays demonstrates that AGN 192836 is 1200-fold selective for the α2A-receptor relative to the α1-receptor, 50-fold selective for the α2A-receptor relative to the α2B-receptor, and 10-fold selective for the α2Areceptor relative to the α2C-receptor. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo AGN 192836 is equally efficacious when compared to brimonidine for the reduction of intraocular pressure upon topical administration to the rabbit and more efficacious than brimonidine for the reduction of blood pressure upon intravenous administration to monkey . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:α adrenergic receptor
All
Chemical Reagents
Biomedicine
Organic raw materials
Inorganic chemical industry
intermediate
Agricultural chemicals
Auxiliaries and catalysts
Fragrances and Flavors
Dyes and Pigments
Daily chemical industry
AGN 192836
CAS number：171102-29-7 molecular formula：C12H13N3O2
overview
compound introduction
Specs
| Chinese alias | - | ||
| English alias | - | ||
| CAS number | 171102-29-7 | molecular formula | C12H13N3O2 |
| molecular weight | 231.25 g/mol | Exact mass | ≥99% |
| PSA | 59.200 Ų | logp | 2.000 |
numbering system
No numbering system information yet
physicochemical properties
No physical and chemical property information yet
Safety information
No safety information yet
Production methods and uses
No production method and use information yet
Related
upstream information
No upstream information yet
downstream information
No downstream information yet
MSDS
Found 0 shareMSDS
